Industry News

• Bristol-Myers Squibb to acquire ZymoGenetics for $885 million  Bristol-Myers Squibb and ZymoGenetics announced that the companies have signed an agreement for the acquisition of ZymoGenetics by Bristol-Myers Squibb, for $9.75 per share in cash with an aggregate purchase price of approximately $885 million.
  Bristol-Myers Squibb Company September 07, 2010  
• Bruker introduces Icon, a high-performance desktop MRI system   Bruker Corporation announced the introduction of the Icon(TM), a new easy-to-use 1 Tesla desktop MRI scanner that combines simplicity with compact dimensions, in order to bring preclinical magnetic resonance imaging (MRI) within reach for a broader range of molecular imaging laboratories.
  Bruker Corporation September 07, 2010  
• Medtronic gains CE mark for enhanced CoreValve® delivery catheter system  Medtronic announced CE Mark approval and the first global launch of the Medtronic CoreValve® delivery system with AccuTrak™ Stability Layer for transcatheter aortic valve implantation. AccuTrak’s proprietary technology provides physicians enhanced control in the deployment of the CoreValve device.
  Medtronic, Inc. September 07, 2010  
• Scott Garrett resigns as chairman, president and CEO of Beckman Coulter  Beckman Coulter announced that Scott Garrett has resigned as Chairman, President and CEO, effective immediately. Garrett will continue as a full-time non-executive employee of the company through January 15, 2011, focusing his attention on aiding the Board of Directors during this transition.
  Beckman Coulter, Inc. September 07, 2010  
• Merck receives FDA Approval for expanded indications for SAPHRIS® sublingual tablets  Merck announced that the FDA has approved two supplemental new drug applications for SAPHRIS® (asenapine) sublingual tablets to expand the product's indications. SAPHRIS is now indicated for the treatment of schizophrenia in adults.
  Merck & Co., Inc. September 07, 2010  
• Twins needed for HIV vaccine study  The HIV Vaccine Trials Unit – Seattle (HVTU), a program of Fred Hutchinson Cancer Research Center, is looking for pairs of identical or fraternal twins living in Seattle and western Washington to participate in a study of the role of genetics and environment on a research HIV vaccine.
  Fred Hutchinson Cancer Research Center September 07, 2010  
• Mayo Clinic researchers receive $11 million for medical genomics  A Mayo Clinic investigator has been awarded an $11.2 million federal research grant for continuing research of pharmacogenomics, the study of the role of genetics in how a person responds to medication.
  Mayo Clinic September 07, 2010  
• Mayo Clinic study finds mild cognitive impairment is more common in men  A Mayo Clinic study found that the prevalence of mild cognitive impairment was 1.5 times higher in men than in women. The research also showed a prevalence rate of 16 percent in the population-based study of individuals aged 70-89 without dementia who live in Olmsted County, Minn.
  Mayo Clinic September 06, 2010  
• MedImmune receives complete response letter on motavizumab   MedImmune announced that it has received a second complete response letter on motavizumab from the FDA which requested evidence from an additional clinical trial that supports a satisfactory risk/benefit profile in the population(s) for which the prophylaxis indication is being requested.
  MedImmune, LLC. September 05, 2010  
• European Commission issues positive decision for approval of Seroquel XR  AstraZeneca announced the European Commission issued a positive decision for the approval of once-daily SEROQUEL XR Extended Release Tablets as an add-on treatment of major depressive episodes in patients with Major Depressive Disorder who had sub-optimal response to antidepressant monotherapy.
  AstraZeneca September 02, 2010  

(previous 10 articles)    (next 10 articles)